| Matthew Erik Cabrera Svendsen, MD | |
|
1000 1st Dr Nw, Austin, MN 55912-2941 | |
| (507) 433-7351 | |
| Not Available |
| Full Name | Matthew Erik Cabrera Svendsen |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 9 Years |
| Location | 1000 1st Dr Nw, Austin, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710373337 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 69928 (Wisconsin) | Secondary |
| 207Q00000X | Family Medicine | 65454 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Hospice | Rochester, MN | Hospice |
| Mayo Clinic Health System - Albert Lea And Austin | Albert lea, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic Health System-southeast Minnesota Region | 4385556703 | 573 |
News Archive
Black patients are significantly less likely than their white counterparts to receive therapy for various kinds of cancer, despite recent efforts to close gaps in treatment, according to a study by researchers at Yale School of Medicine published in the January 7 online issue of the journal Cancer.
Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.
The new German-Canadian lab HIBALL aims to create a microscopic 3D map of functional neuroanatomy at the cellular level with the help of high-performance computing and artificial intelligence.
APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.
› Verified 9 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891701637 PECOS PAC ID: 4385556703 Enrollment ID: O20031104000408 |
News Archive
Black patients are significantly less likely than their white counterparts to receive therapy for various kinds of cancer, despite recent efforts to close gaps in treatment, according to a study by researchers at Yale School of Medicine published in the January 7 online issue of the journal Cancer.
Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.
The new German-Canadian lab HIBALL aims to create a microscopic 3D map of functional neuroanatomy at the cellular level with the help of high-performance computing and artificial intelligence.
APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew Erik Cabrera Svendsen, MD 1000 1st Dr Nw, Austin, MN 55912-2941 Ph: (507) 433-7351 | Matthew Erik Cabrera Svendsen, MD 1000 1st Dr Nw, Austin, MN 55912-2941 Ph: (507) 433-7351 |
News Archive
Black patients are significantly less likely than their white counterparts to receive therapy for various kinds of cancer, despite recent efforts to close gaps in treatment, according to a study by researchers at Yale School of Medicine published in the January 7 online issue of the journal Cancer.
Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.
The new German-Canadian lab HIBALL aims to create a microscopic 3D map of functional neuroanatomy at the cellular level with the help of high-performance computing and artificial intelligence.
APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.
› Verified 9 days ago
Olaf Js Samuelson, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-433-7351 | |
Bosheng Yang, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-434-1092 Fax: 507-434-1477 | |
Erin Kastl, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-433-7351 | |
James Robert Burke, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-434-1092 Fax: 507-434-1477 | |
Robert P. Bonacci, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-433-7351 | |
Crina L. Manole Weddle, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-433-7351 | |
Wei-lin Jung, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-434-1092 Fax: 507-434-1477 |